Catheter Precision, Inc. announced on February 4, 2025, the closing of its previously announced acquisition of PeriKard, LLC. This all-stock transaction was completed within the anticipated timeline.
The consideration for the acquisition involved the issuance of 275,000 shares of VTAK common stock, valued at $113 thousand. Additionally, $6 thousand in direct transaction costs were incurred.
The acquired patent related to pericardial access technology was deemed in-process research and development (IPR&D) with no alternative future use at the time of acquisition. Consequently, the entire cost of $119 thousand was expensed in the first quarter of 2025. This acquisition complements Catheter Precision's emphasis on the ventricular therapeutic market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.